Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anthracycline-antibody conjugates for cancer therapy

Anthracycline-antibody conjugates for cancer therapy

US Patent 8895013 · Granted Nov 25, 2014

Estimated economic value: $5,310,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for hemoclip deployment2025
Method of preparing zirconium-89 oxine complex2025
Tool for hemostasis and tissue approximation2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Antibody-drug conjugates and uses thereof2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2023
Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy2022
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PAR2022
Zirconium-89 oxine complex as a cell labeling agent for positron emission tomogr2021
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors rel2021
Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malign2021